ValuEngine upgraded shares of iCAD (NASDAQ:ICAD) from a strong sell rating to a sell rating in a research note issued to investors on Thursday morning.
Shares of iCAD (NASDAQ:ICAD) traded up $0.44 on Thursday, reaching $4.00. The company’s stock had a trading volume of 78,000 shares, compared to its average volume of 61,067. The firm has a market cap of $65.44, a P/E ratio of -4.88 and a beta of 1.54. iCAD has a 52-week low of $3.13 and a 52-week high of $6.07. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.95 and a quick ratio of 1.67.
iCAD (NASDAQ:ICAD) last announced its earnings results on Wednesday, November 8th. The technology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.43 million. iCAD had a negative return on equity of 47.31% and a negative net margin of 49.16%. equities research analysts forecast that iCAD will post -0.62 EPS for the current fiscal year.
iCAD Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.